Cogent Biosciences, Inc.
COGT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.92 | -0.34 | -0.23 | 0.07 |
| FCF Yield | -25.72% | -33.40% | -18.48% | -18.20% |
| EV / EBITDA | -2.64 | -2.11 | -4.16 | -1.54 |
| Quality | ||||
| ROIC | -100.23% | -75.23% | -53.41% | -34.17% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.80 | 0.85 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -33.21% | -24.64% | -107.50% | -68.71% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 0.17 | 0.89 | 2.87 |
| Interest Coverage | 0.00 | 0.00 | -37.06 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -996.31 | -1,083.91 | -362.76 | -8,648.27 |